Prevalence and prognostic significance of c-KIT mutations in core binding factor acute myeloid leukemia: A comprehensive large-scale study from a single Chinese center-Reference-Cited by-同舟云学术

Prevalence and prognostic significance of c-KIT mutations in core binding factor acute myeloid leukemia: A comprehensive large-scale study from a single Chinese center

Published:2014-12 Issue:12 Volume:38 Page:1435-1440
ISSN:0145-2126
Container-title:Leukemia Research
language:en
Short-container-title:Leukemia Research

Author:

Qin Ya-Zhen,Zhu Hong-Hu,Jiang Qian,Jiang Hao,Zhang Le-Ping,Xu Lan-Ping,Wang Yu,Liu Yan-Rong,Lai Yue-Yun,Shi Hong-Xia,Jiang Bin,Huang Xiao-Jun

Funder

Nature Science Foundation of China

Beijing Municipal Science and Technology Program

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference39 articles.

1. Functional domains of the t(8;21) fusion protein AML-1/ETO;Lenny;Oncogene,1995

2. Fusion between transcription factor CBF beta/PEBP2 beta and a myosin heavy chain in acute myeloid leukemia;Liu;Science,1993

3. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 Trial;Grimwade;Blood,1998

4. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype;Bloomfield;Cancer Res,1998

5. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)

Cited by 57 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of monocytic differentiation on acute myeloid leukemia patients treated with venetoclax and hypomethylating agents;Cancer Medicine;2024-07

2. Pediatric acute myeloid leukemia with t(8;21) and KIT mutation treatment with avapritinib post-stem cell transplantation: a report of four cases;Annals of Hematology;2024-05-28

3. Usefulness of KIT mutant transcript levels for monitoring measurable residual disease in t (8;21) acute myeloid leukemia;Hematological Oncology;2024-03

4. A multicenter retrospective comparison between systemic mastocytosis with t(8;21) AML and KIT mutant t(8;21) AML;Blood Advances;2024-02-15

5. CPX-351 and allogeneic stem cell transplant for a therapy-related acute myeloid leukemia that developed after treatment of acute promyelocytic leukemia: a case report and review of the literature;Frontiers in Oncology;2024-01-25